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BACKGROUND: Many patients with heart failure and reduced 
ejection fraction (HFrEF) have chronic kidney disease that complicates 
pharmacological management and is associated with worse outcomes. 
We assessed the safety and efficacy of dapagliflozin in patients with HFrEF, 
according to baseline kidney function, in the DAPA-HF trial (Dapagliflozin 
and Prevention of Adverse-outcomes in Heart Failure). We also examined 
the effect of dapagliflozin on kidney function after randomization.
METHODS: Patients who have HFrEF with or without type 2 diabetes and 
an estimated glomerular filtration rate (eGFR) ≥30 mL·min–1·1.73 m–2 were 
enrolled in DAPA-HF. We calculated the incidence of the primary outcome 
(cardiovascular death or worsening heart failure) according to eGFR 
category at baseline (<60 and ≥60 mL·min–1·1.73 m–2) and used eGFR 
at baseline as a continuous measure, as well. Secondary cardiovascular 
outcomes and a prespecified composite renal outcome (≥50% sustained 
decline eGFR, end-stage renal disease, or renal death) were also 
examined, along with a decline in eGFR over time.
RESULTS: Of 4742 patients with a baseline eGFR, 1926 (41%) had eGFR 
<60 mL·min–1·1.73 m–2. The effect of dapagliflozin on the primary and 
secondary outcomes did not differ by eGFR category or examining eGFR 
as a continuous measurement. The hazard ratio (95% CI) for the primary 
end point in patients with chronic kidney disease was 0.71 (0.59–0.86) 
versus 0.77 (0.64–0.93) in those with an eGFR ≥60 mL·min–1·1.73 m–2 
(interaction P=0.54). The composite renal outcome was not reduced 
by dapagliflozin (hazard ratio=0.71 [95% CI, 0.44–1.16]; P=0.17) but 
the rate of decline in eGFR between day 14 and 720 was less with 
dapagliflozin, –1.09 (–1.40 to –0.77) versus placebo –2.85 (–3.17 to 
–2.53) mL·min–1·1.73 m–2 per year (P<0.001). This was observed in those 
with and without type 2 diabetes (P for interaction=0.92).
CONCLUSIONS: Baseline kidney function did not modify the benefits 
of dapagliflozin on morbidity and mortality in HFrEF, and dapagliflozin 
slowed the rate of decline in eGFR, including in patients without diabetes.
REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: 
NCT03036124.
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Impaired renal function is common in patients with heart failure and reduced ejection fraction (HFrEF) and up to 50% have chronic kidney disease (CKD) de-
fined as an estimated glomerular filtration rate (eGFR) 
<60 mL·min–1·1.73 m–2.1 CKD is associated with con-
ditions that lead to the development of heart failure, 
such as atherosclerosis and hypertension, and common 
comorbidities in heart failure such as diabetes and ane-
mia, as well. Once heart failure develops, renal function 
declines and this is associated with a poorer prognosis.2 
In part, this may be because the use of many of the 
therapies known to improve morbidity and mortality in 
HFrEF is restricted by kidney function and may even be 
impossible in patients with very low eGFR. Yet, para-
doxically, it is patients with CKD who potentially derive 
the greatest absolute benefit from treatment with phar-
macotherapy because of their higher event rates.3
Sodium-glucose cotransporter 2 (SGLT2) inhibitors 
have recently been shown to improve cardiovascular 
outcomes in patients with type 2 diabetes.4–7 In addi-
tion, they slow the rate of decline in kidney function in 
these patients and reduce renal morbidity and mortal-
ity in patients with type 2 diabetes and kidney dysfunc-
tion.8 In the DAPA-HF trial (Dapagliflozin and Prevention 
of Adverse-outcomes in Heart Failure), the SGLT2 inhibi-
tor dapagliflozin reduced the incidence of the primary 
composite outcome of cardiovascular death or worsen-
ing heart failure (HF) in patients who had HFrEF with 
and without type 2 diabetes.9 In this study, we explored 
whether the effect of dapagliflozin varied according to 
baseline renal function. We also examined the effect of 
dapagliflozin on kidney function and renal outcomes.
METHODS
The DAPA-HF trial randomly assigned patients with HFrEF 
with and without type 2 diabetes in a double-blind, pla-
cebo-controlled, event-driven trial.9–11 The SGLT2 inhibitor 
dapagliflozin at a dose of 10 mg once daily, in addition to 
standard care, was compared with matching placebo. The 
design, baseline characteristics, and primary results have 
been published.9–11 The Ethics Committee of the 410 partici-
pating institutions in 20 countries approved the protocol; all 
patients gave written informed consent. The corresponding 
author had full access to all the trial data and takes respon-
sibility for its integrity and the data analysis. The data that 
support the findings of this study are available from the cor-
responding author on reasonable request.
Study Patients
The trial included patients with HF with a left ventricu-
lar ejection fraction ≤40%, ≥18 years of age, New York 
Heart Association functional class II to IV, and an elevated 
N-terminal pro-B-type natriuretic peptide level, and who were 
receiving optimal pharmacological and device therapy. The 
trial protocol required guideline-recommended medications, 
including β-blocker, unless contraindicated/not tolerated. The 
main exclusion criteria included type 1 diabetes, symptomatic 
hypotension/systolic blood pressure <95 mm Hg, eGFR <30 
mL·min–1·1.73 m–2, or “unstable or rapidly progressing renal 
disease,” in the view of the investigator.
Measurement of Kidney Function and 
eGFR Subgroup Analysis
Blood samples were taken at randomization, at 14 days, 
and at 2, 4, 8, and 12 months, and every 4 months there-
after. Creatinine was measured in a central laboratory and 
eGFR was calculated using the Chronic Kidney Disease 
Epidemiology Collaboration equation. The prespecified sub-
group analysis of the efficacy of dapagliflozin according to 
baseline eGFR divided patients <60 and ≥60 mL·min–1·1.73 
m–2. We also examined the efficacy of dapagliflozin by using 
eGFR as a continuous measure.
Prespecified Outcomes
The primary outcome of DAPA-HF was the composite of 
worsening heart failure (HF hospitalization or urgent visit 
for HF requiring intravenous therapy) or cardiovascular 
death, whichever occurred first. Prespecified secondary end 
points included HF hospitalization or cardiovascular death; 
HF hospitalizations (first and recurrent) and cardiovascular 
deaths. The prespecified secondary renal outcome was a 
composite of ≥50% sustained decline eGFR or end-stage 
renal disease or renal death. Sustained was defined as last-
ing at least 28 days and end-stage renal disease was defined 
as a sustained eGFR of <15 mL·min–1·1.73 m–2 or chronic 
dialysis or renal transplantation. Change from baseline to 
8 months in Kansas City Cardiomyopathy Questionnaire-
total symptom score12 was examined with the proportion 
of patients having a ≥5 point increase or decrease in their 




• The sodium-glucose cotransporter 2 inhibitor dapa-
gliflozin slowed the rate of decline in estimated 
glomerular filtration rate in patients with heart fail-
ure with reduced ejection fraction both in patients 
with and without type 2 diabetes.
• There was no difference in the efficacy of dapa-
gliflozin by baseline kidney function in preventing 
the risk of cardiovascular death or worsening heart 
failure.
What Are the Clinical Implications?
• Patients with heart failure with reduced ejection 
fraction and impaired kidney function will benefit 
from the addition of a sodium-glucose cotrans-
porter 2 inhibitor to standard therapies.
• Use of sodium-glucose cotransporter 2 inhibitor in 
this population will slow the progression of kidney 
dysfunction, but whether this translates into reduc-
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One prespecified exploratory end point related to kidney 
function was the number of cases of doubling of serum cre-
atinine. Doubling of serum creatinine (in comparison with the 
most recent central laboratory measurement) was adjudicated 
and defined as a doubling of serum creatinine in comparison 
with the most recent central laboratory result and could be trig-
gered by a local laboratory result or a central laboratory result. 
This could represent a chronic or more acute kidney injury.
Prespecified safety analyses included any serious adverse 
event, adverse events related to study drug discontinuation, 
and adverse events of interest that specifically included renal 
adverse events.
In addition to these prespecified outcomes, the post hoc 
outcome of the slope of change from baseline in eGFR over 
time according to randomized treatment was calculated as 
described under Statistical Analysis.
Statistical Analysis
Baseline characteristics were summarized as means (SDs), 
median (interquartile ranges), or percentages. We used the 
Kaplan-Meier estimate and Cox proportional-hazards models, 
stratified by diabetes status, and adjusted for history of HF hos-
pitalization (except for all-cause death) and treatment-group 
assignment to examine the primary and secondary outcomes. 
The interaction between baseline eGFR and treatment on the 
primary and secondary outcomes was modeled as a fractional 
polynomial and graphed.14 The renal composite outcome was 
evaluated in a Cox model stratified by diabetes status adjusted 
for baseline eGFR and treatment group. A semiparametric 
proportional-rates model (described by Lin et al15) was used to 
analyze total (including recurrent) HF hospitalizations account-
ing for the risk of cardiovascular death as a terminal event. 
Repeated-measures mixed-effect models were used to exam-
ine the slope of change in eGFR over time according to ran-
domized treatment. These were adjusted for baseline values, 
visit, randomized treatment, and interaction of treatment and 
visit with a random intercept and slope per patient with an 
unstructured covariance structure. There were 2 clear phases to 
the slope of eGFR, an initial decline and then a slower decline. 
The slope of change in eGFR in each randomization group 
(expressed as a decrease per mL·min–1·1.73 m–2 were compared 
between day 0 (randomization) and day 14 and then from day 
14 to day 720 of follow-up. In an exploratory analysis, to exam-
ine the potential survivor bias introduced into the analyses of 
eGFR slopes, we also modeled eGFR jointly with all-cause mor-
tality.16 We examined the slope of eGFR in patients with and 
without diabetes at baseline. Safety analyses were performed 
in randomly assigned patients who had received at least 1 dose 
of dapagliflozin or placebo. The interaction between CKD and 
randomized treatment on the occurrence of the prespecified 
safety outcomes was tested in a logistic regression model with 
the baseline CKD group and randomized therapy and their 
interaction term as the only factors in the model. All analyses 
were conducted using Stata version 16.1. A P value of <0.05 
was considered statistically significant.
RESULTS
At baseline, an eGFR could be calculated in 4743 patients 
and 1926 (41%) had a value <60 mL·min–1·1.73 m–2 
(Table 1). Participants with lower eGFR were consider-
ably older (71 versus 63 years, respectively), more were 
women (28% versus 20%), and more had an ischemic 
cause (61% versus 53%), in comparison with those 
with an eGFR ≥60 mL·min–1·1.73 m–2. Patients with an 
eGFR <60 mL·min–1·1.73 m–2 had a higher N-terminal 
pro-B-type natriuretic peptide, lower heart rate, and 
more often had a history of atrial fibrillation, myocardial 
infarction, hypertension, and type 2 diabetes (Table 1). 
Patients with eGFR <60 mL·min–1·1.73 m–2 were more 
often treated with a diuretic, but less frequently treated 
with a renin-angiotensin system blocker or mineralo-
corticoid receptor antagonist, in comparison with those 
with an eGFR ≥60 mL·min–1·1.73 m–2. In participants 
with type 2 diabetes at baseline, patients with a lower 
eGFR were more likely than individuals with an eGFR 
≥60 mL·min–1·1.73 m–2 to be treated with a dipeptidyl 
peptidase 4 inhibitor and insulin (Table 1).
Cardiovascular Outcomes According to 
Baseline eGFR
Primary and Secondary Trial Outcomes
The incidence rates of the primary and secondary 
outcomes of the trial were higher in those with CKD 
at baseline (Table 2 and Figure I in the Data Supple-
ment). The efficacy of dapagliflozin in preventing the 
primary outcome of cardiovascular death or worsen-
ing HF did not differ between those with an eGFR of 
<60 mL·min–1·1.73 m–2 and individuals with an eGFR 
≥60 mL·min–1·1.73 m–2 (P for interaction=0.54). The 
efficacy of dapagliflozin in preventing cardiovascular 
death, HF hospitalizations, or urgent HF visits, the 
total HF hospitalizations and all-cause death also did 
not differ by eGFR group (Table 2). The results were 
similar when eGFR was treated as a continuous vari-
able, P for interaction=0.77 (Figure 1 and Figure II in 
the Data Supplement).
Applying the overall relative risk reduction (26%) to 
the placebo group event rate in those with an eGFR 
of <60 mL·min–1·1.73 m–2 gave a reduction with dapa-
gliflozin of 52 fewer patients experiencing a primary 
outcome per 1000 person-years of follow-up. The 
equivalent absolute risk reduction in patients ≥60 
mL·min–1·1.73 m–2 was estimated as 34 fewer patients 
per 1000 person-years of follow-up. The correspond-
ing reductions in all-cause mortality were 21 and 13, 
respectively, per 1000 person-years of follow-up.
The proportion of patients with a ≥5 point deterio-
ration in Kansas City Cardiomyopathy Questionnaire 
score (worsening) was lower in those randomly as-
signed to dapagliflozin, and the proportion of patients 
with a ≥5 point improvement in Kansas City Cardiomy-
opathy Questionnaire score (improvement) was higher 
in those randomly assigned to dapagliflozin, irrespec-
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 P valuen=1926 n=2816
Baseline eGFR, mL·min–1·1.73 m–2 47.0±8.0 78.7±13.5 -
Age, y 70.9±9.0 63.2±11.0 <0.001
Sex <0.001
  Women 534 (27.7) 575 (20.4)  
  Men 1392 (72.3) 2241 (79.6)  
Geographic region <0.001
  Asia/Pacific 365 (19.0) 731 (26.0)  
  Europe 891 (46.3) 1263 (44.9)  
  North America 305 (15.8) 370 (13.1)  
  South America 365 (19.0) 452 (16.1)  
New York Heart Association class  0.043
  II 1267 (65.8) 1934 (68.7)  
  III 645 (33.5) 853 (30.3)  
  IV 14 (0.7) 29 (1.0)  
Heart rate, bpm 70.7±11.6 72.0±11.7 <0.001
Baseline systolic blood pressure, mm Hg 121.7±16.2 121.9±16.4  0.70
Baseline ejection fraction, % 31.3±6.6 30.9±6.9  0.069
Baseline N-terminal pro-B-type natriuretic peptide, pg/
mL, median (interquartile range)
1823.8 (1060.2–3326.2) 1261.1 (769.9–2207.7) <0.001
Body mass index, kg/m2 28.4±5.8 28.0±6.0  0.009
Main cause of heart failure <0.001
  Ischemic 1174 (61.0) 1498 (53.2)  
  Nonischemic 605 (31.4) 1082 (38.4)  
  Unknown 147 (7.6) 236 (8.4)  
Previous heart failure hospitalization 951 (49.4) 1298 (46.1)  0.026
Type 2 diabetes at baseline* 982 (51.0) 1157 (41.1) <0.001
History of atrial fibrillation 880 (45.7) 938 (33.3) <0.001
History of myocardial infarction 909 (47.2) 1182 (42.0) <0.001
History of hypertension 1561 (81.0) 1960 (69.6) <0.001
History of implantable cardioverter defibrillator or CRT-
defibrillator
568 (29.5) 673 (23.9) <0.001
CRT-pacemaker or CRT-defibrillator 186 (9.7) 168 (6.0) <0.001
Diuretic 1835 (95.3) 2597 (92.2) <0.001
Angiotensin-converting enzyme inhibitor/angiotensin 
receptor blocker
1542(80.1) 2408(85.5) <0.001
Angiotensin receptor neprilysin inhibitor 221 (11.5) 287 (10.2)  0.16
Angiotensin-converting enzyme inhibitor/angiotensin 
receptor blocker/angiotensin receptor neprilysin inhibitor
1755 (91.1) 2685 (95.3) <0.001
β-Blocker 1838 (95.4) 2718 (96.5)  0.058
Mineralocorticoid receptor antagonist, 1296 (67.3) 2074 (73.7) <0.001
Digoxin 338 (17.5) 549 (19.5)  0.091
Patients with type 2 diabetes at baseline*    
Hemoglobin A1c, % 6.6±1.4 6.4±1.3 <0.001
Biguanide 406 (21.1) 624 (22.2)  0.38
Sulfonylurea 198 (10.3) 242 (8.6)  0.049
Dipeptidyl peptidase 4 inhibitor 164 (8.5) 146 (5.2) <0.001
Glucagon-like peptide 1- receptor agonist 15 (0.8) 6 (0.2)  0.004
Insulin 304 (15.8) 236 (8.4) <0.001
CRT indicates cardiac resynchronization therapy; and eGFR, estimated glomerular filtration rate.
*Eighty-two patients in the dapagliflozin group and 74 in the placebo group had previously undiagnosed diabetes, which was defined 
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Prespecified Composite Renal Outcome
The incidence of the prespecified renal composite out-
come was higher in the patients with lower eGFR at 
baseline than in those with an eGFR ≥60 mL·min–1·1.73 
m–2 (Table  3). Although the rate was lower in those 
randomly assigned to dapagliflozin, the difference was 
not statistically significant (hazard ratio, 0.71 [95% CI, 
0.44–1.16]; P=0.17; Table 3 and Figure 2). The major 
components of the composite were ≥50% decline in 
eGFR and the need for sustained dialysis. Although 
there were fewer patients with a ≥50% decline in eGFR 
in the dapagliflozin group (n=14) than in the placebo 
group (n=23), the number of patients started on dialy-
sis was identical in the 2 treatment groups (n=16). No 
patient received a kidney transplant.
There was no interaction between eGFR group and 
the effect of dapagliflozin on the renal composite out-
come, P for interaction=0.19 (Table 4 and Figure III in 
the Data Supplement). There were too few events to do 
a meaningful analysis of the components of the renal 
composite outcome according to eGFR category.
There was also no interaction between baseline dia-
betes status and the effect of dapagliflozin on the renal 
composite outcome, P for interaction between baseline 
diabetes and the effect of randomized treatment=0.87 
(Figure IV in the Data Supplement).
Table 2. Efficacy of Dapagliflozin on the Primary and Secondary Outcomes According to Baseline eGFR
Outcome
eGFR <60 mL·min–1·1.73 m–2 eGFR ≥60 mL·min–1·1.73 m–2
P value for 
interactionPlacebo (n=964) Dapagliflozin (n=962) Placebo (n=1406) Dapagliflozin (n=1410)
Cardiovascular death or HF hospitalization/urgent HF visit
  No. (%) 254 (26.4) 191 (19.9) 248 (17.6) 195 (13.9) 0.54
  Rate per 100 patient-years 
(95% CI)
20.0 (17.7–22.6) 14.5 (12.6–16.7) 13.0 (11.5–14.7) 9.9 (8.6–11.4)
  HR 0.72 (0.59–0.86) 0.76 (0.63–0.92)
Cardiovascular death
  No. (%) 134 (13.9) 119 (12.4) 139 (9.9) 108 (7.7) 0.44
  Rate per 100 patient-years 
(95% CI)
9.7 (8.2–11.5) 8.6 (7.2–10.3) 6.9 (5.8–8.1) 5.3 (4.4–6.3)
  HR 0.88 (0.69–1.13) 0.76 (0.59–0.98)
HF hospitalization/urgent HF visit
  No. (%) 173 (18.0) 120 (12.5) 153 (10.9) 117 (8.3) 0.39
  Rate per 100 patient-years 
(95% CI)
13.7 (11.8–15.9) 9.1 (7.6–10.9) 8.0 (6.8–9.4) 5.9 (5.0–7.1)
  HR 0.66 (0.52–0.83) 0.75 (0.59–0.95)
Total (recurrent) HF hospitalizations/cardiovascular death
  No. 374 301 368 266 0.50
  Rate per 100 patient-years 
(95% CI)
26.8 (19.2–24.1) 21.5 (19.2–24.1) 18.0 (16.3–20.0) 12.8 (11.4–14.4)
  HR 0.79 (0.64–0.97) 0.71 (0.58–0.93)
All-cause death
  No. (%) 168 (17.4) 143 (14.9) 161 (11.5) 133 (9.4) 0.80
  Rate per 100 patient-years 
(95% CI)
12.2 (10.5–14.2) 10.3 (8.8–12.2) 7.9 (6.8–9.3) 6.5 (5.5–7.7)
  HR 0.85 (0.68–1.07) 0.81 (0.64–1.02)
Kansas City Cardiomyopathy Questionnaire
  Mean change at 8 mo (SD) 6.3 (18.9) 3.0 (19.2) 6.0 (18.5) 3.5 (19.3)  
  Proportion with increase in 
score ≥5 at 8 mo
49.2 (46.0-52.5) 55.3 (52.0 -58.7) 52.1 (49.3-54.9) 60.3 (57.5-63.0)  
  Odds ratio for increase in 
score ≥5 at 8 mo
1.13 (1.02–1.24) 1.17 (1.08–1.27) 0.52
  Proportion with decrease in 
score ≥5 at 8 mo
30.0 (25.0–31.0) 33.7 (30.6–36.8) 32.3 (29.7–34.8) 23.5 (21.2–25.8)  
  Odds ratio for decrease in 
score ≥5 at 8 mo
0.88 (0.79–0.97) 0.81 (0.74–0.88) 0.23
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Doubling of Serum Creatinine
This prespecified exploratory outcome of doubling of 
serum creatinine relative to the last obtained laboratory 
value occurred in 43 patients (1.8%) in the dapagliflozin 
group and 77 patients (3.2%) in the placebo group (haz-
ard ratio, 0.56 [95% CI, 0.39–0.82]; P=0.003; Figure V 
in the Data Supplement). In those with an eGFR ≥60 
mL·min–1·1.73 m–2, 26 patients (1.8%) and 41 (2.9%) 
patients in the dapagliflozin and placebo groups, re-
spectively, had a doubling of serum creatinine (hazard 
ratio, 0.62 [95% CI, 0.38–1.01]); in those with an eGFR 
<60 mL·min–1·1.73 m–2 the numbers were 17 (1.8%) 
and 36 (3.7%), respectively (hazard ratio, 0.74 [95% 
CI, 0.26–0.83]; P for interaction=0.74).
Change in eGFR Over Time
Kidney function declined over time in both the placebo 
group and the dapagliflozin group (Figure 3). There was 
a small initial decrease in eGFR related to the introduc-
tion of dapagliflozin, demonstrated by the change from 
baseline to day 14. However, after day 14, the rate of de-
cline was steeper in the placebo group than in the dapa-
gliflozin group. Between day 14 and day 720, the change 
in eGFR in the dapagliflozin group was about one-third of 
that in the placebo group: change in eGFR mL·min–1·1.73 
m–2 per year in the dapagliflozin group –1.09 (95% CI, 
–1.40 to –0.77) and in the placebo group –2.85 (95% 
CI, –3.17 to –2.53), P for difference in slopes<0.001. The 
results from the exploratory joint model where eGFR was 
modeled jointly with all-cause mortality were not differ-
ent than the prespecified slope analyses. In patients with 
and without type 2 diabetes at baseline, we observed 
similar changes in eGFR over time in the dapagliflozin and 
placebo groups (P for interaction=0.92; Figure 4).
The same pattern was observed in patients with an 
eGFR <60 or ≥60 mL·min–1·1.73 m–2 (Figure VI in the 
Data Supplement).
Safety and Adverse Events
In patients exposed to at least 1 dose of study drug, 
there were fewer renal adverse events in the group 
randomly assigned to dapagliflozin: 153 (6.5%) versus 
170 (7.2%) in the placebo group (P=0.36). Serious re-
nal adverse events occurred significantly less frequently 
in those randomly assigned to dapagliflozin: 38 (1.6%) 
versus 65 (2.7%) in the placebo group (P=0.009). There 
was no difference in the numbers of individuals stop-
ping study drug because of a renal adverse event (8 in 
the dapagliflozin group, 9 in the placebo group). Other 
prespecified safety outcomes are shown in Table 5.
DISCUSSION
In DAPA-HF, the benefits of dapagliflozin on the pri-
mary and secondary cardiovascular outcomes were 
Figure 1. Effect of dapagliflozin on the primary outcome by eGFR at 
baseline.
The blue line represents continuous hazard ratio, and the gray area represents 
the 95% CI with the overall hazard ratio for the effect of dapagliflozin on 
the primary outcome given by the dashed red line. eGFR indicates estimated 
glomerular filtration rate.
Table 3. Renal Composite Outcome and Its Components in the DAPA-HF Trial
Composite outcome
Placebo Dapagliflozin
Hazard ratio (95%CI), 
P valuen (%)
Rate per 100 patient-
years (95% CI) n (%)
Rate per 100 patient-
years (95% CI)
Renal composite
  ≥50% sustained decline eGFR 
or end-stage renal disease or 
renal death
39 (1.6) 1.20 (0.88–1.65) 28 (1.2) 0.85 (0.59–1.23) 0.71 (0.44–1.16), 0.17
Components of the composite
  ≥50% sustained decline eGFR 23 (1.0) 0.71 (0.47–1.07) 14 (0.6) 0.43(0.25–0.72) 0.60 (0.31–1.16), 0.13
  End-stage renal disease 16 (0.7) 0.49 (0.30–0.80) 16 (0.7) 0.48 (0.30–0.79) 1.00 (0.50–1.99), 0.99
   Sustained eGFR <15 
mL·min–1·1.73 m–2 
0 – 1 (0.04) – –
   Chronic dialysis treatment 16 (0.7) 0.49 (0.30–0.80) 16 (0.7) 0.48 (0.30–0.80) 1.00 (0.50–1.99), 0.99
   Renal transplant 0 – 0 – –
  Renal death 1 (0.04) – 0 – –
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consistent in patients with and without low eGFR, with 
greater absolute risk reductions in patients with lower 
eGFR. Although the incidence of the renal composite 
outcome was numerically lower in patients treated 
with dapagliflozin, in comparison with placebo, the 
difference between treatments was not statistically sig-
nificant. However, dapagliflozin did reduce the risk of 
doubling serum creatinine relative to the last labora-
tory measure and of serious renal adverse events, and 
it attenuated the decrease in eGFR over time in com-
parison with placebo. This slowing of eGFR decline was 
observed in patients with and without low eGFR and in 
those with and without type 2 diabetes.
That the benefits of dapagliflozin on the primary and 
secondary cardiovascular outcomes were consistent in 
patients with and without low eGFR is important, be-
cause these patients are at much higher risk than pa-
tients with preserved kidney function (as observed in 
this study) and often cannot be treated with alterna-
tive life-saving therapies.17 Specifically, underutiliza-
tion of renin-angiotensin system blockers and miner-
alocorticoid receptor antagonists is well recognized in 
patients with CKD and, more recently, evidence has 
been presented that the benefits of β-blockers are at-
tenuated in patients with marked reductions in eGFR.18 
Consequently, any treatment that is effective in these 
high-risk individuals, and well-tolerated, is a potentially 
important advance in their care. In addition to being 
effective, dapagliflozin appeared to have an acceptable 
safety profile in people with CKD. Although patients 
with CKD experienced more adverse effects of all types 
than patients without CKD, they did not experience 
more adverse effects with dapagliflozin in comparison 
with placebo. Similarly, patients with CKD were more 
likely to stop study drug than those without CKD, but 
patients with CKD were no more likely to stop dapa-
gliflozin than placebo, and only ≈13% of patients dis-
continued dapagliflozin for any reason during follow-
up. Our tolerability and safety findings are consistent 
with those of the CREDENCE trial (Evaluation of the 
Effects of Canagliflozin on Renal and Cardiovascular 
Outcomes in Participants With Diabetic Nephropathy), 
the first trial to exclusively enroll patients with type 2 
diabetes and CKD8 and the more recent DAPA-CKD trial 
(Dapagliflozin and Prevention of Adverse Outcomes in 
Chronic Kidney Disease).19,20
When DAPA-HF was designed initially, the renal ben-
efits of SGLT2 inhibitors had not been established and 
there was uncertainty about the renal safety of using 
these agents in HFrEF. We knew that SGLT2 inhibitors 
had diuretic activity and caused a small decline in eGFR. 
Therefore, adding a SGLT2 inhibitor on top of conven-
tional diuretics, renin-angiotensin system blockers, and 
mineralocorticoid receptor antagonists in these patients 
was a potential concern, especially because many were 
expected to have CKD at baseline. These concerns were 
not realized. Although we did not observe a statisti-
cally significant reduction in the prespecified renal com-
posite outcome with dapagliflozin, there were a few 
of these events in DAPA-HF. The effect of dapagliflozin 
on this outcome was broadly consistent with the effect 
of other SGLT2 inhibitors on similar composite renal 
Figure 2. Effect of dapagliflozin on the 
prespecified renal composite outcome.
Renal outcome was a composite of ≥50% 
sustained decline estimated glomerular filtration 
rate or end-stage renal disease or renal death 
in DAPA-HF (Dapagliflozin and Prevention of 
Adverse-outcomes in Heart Failure). HR indi-
cates hazard ratio.
Table 4. Renal Composite Outcome by Baseline eGFR
Outcome
eGFR <60 mL·min–1·1.73 m–2 eGFR ≥60 mL·min–1·1.73 m–2






No. (%) 19 (2.0) 18 (1.9) 20 (1.4) 10 (0.7) 0.19
Rate (95% CI) 1.5 (0.9–2.3) 1.4 (0.9–2.2) 1.0 (0.7–1.6) 0.5 (0.3–0.9)
Hazard ratio 0.95 (0.50–1.82) 0.49 (0.23–1.06)
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outcomes in trials including patients with type 2 dia-
betes, taking account of baseline kidney function and 
duration of follow-up, which are major determinants 
of the number of renal events observed. Moreover, in 
the recent EMPEROR-Reduced trial (Empagliflozin Out-
come Trial in Patients with Chronic Heart Failure and a 
Reduced Ejection Fraction), SGLT2 inhibition did reduce 
renal events significantly, although that trial used a dif-
ferent renal composite outcome and had more renal 
events than in DAPA-HF (88 versus 67).21
Although we did not observe a statistically sig-
nificant reduction in the prespecified renal composite 
outcome, dapagliflozin did reduce the risk of the dou-
bling of serum creatinine concentration relative to the 
last visit and serious renal adverse events. The reduced 
risk of doubling of creatinine concentration is notable, 
given that previous studies have shown that worsening 
kidney function identified by even modest increases in 
creatinine (or equivalent reductions in eGFR) are asso-
ciated with worse cardiovascular outcomes in patients 
with HFrEF.3,17,18,22
We also observed a significant reduction in the rate 
of eGFR decline over time in the dapagliflozin group, 
an analysis for which we had more statistical power. 
Figure 3. Effect of dapagliflozin on change in eGFR from baseline in DAPA-HF (Dapagliflozin and Prevention of Adverse-outcomes in Heart Failure).
Slope in eGFR from day 0 to 14 from baseline is the slope per mL·min–1·1.73 m–2 for over 14 days and from 14 to 720 days expressed as a slope per mL·min–1·1.73 
m–2 per year. eGFR indicates estimated glomerular filtration rate.
Figure 4. Effect of dapagliflozin, by baseline diabetes status on eGFR.
Effect of dapagliflozin by baseline diabetes status (includes 82 patients taking dapagliflozin and 74 patients on placebo with previously undiagnosed diabetes, that 
is, 2 hemoglobin A1c ≥6.5% [≥48 mmol/mol]) on change in eGFR from baseline in DAPA-HF (Dapagliflozin and Prevention of Adverse-outcomes in Heart Failure). 
Slope in eGFR from day 0 to 14 from baseline is the slope per mL·min–1·1.73 m–2 per over 14 days and from 14 to 720 days expressed as a slope per mL·min–1·1.73 
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The rate of decline in eGFR in patients in the place-
bo group in DAPA-HF was 2.87 (95% CI, 3.19–2.55) 
mL·min–1·1.73 m–2 per year, which was steeper than 
in CANVAS (Canagliflozin Cardiovascular Assessment 
Study; 0.85 mL) and EMPA-REG OUTCOME (Empa-
gliflozin Cardiovascular Outcome Event Trial in Type 2 
Diabetes Mellitus Patients; 1.67 mL), but, as expected, 
less than in CREDENCE (4.7 mL).
More recently, in a large trial using empagliflozin in 
patients with HFrEF, the rate of decline in eGFR was 
2.28 (SD 0.23) mL·min–1·1.73 m–2 per year, which was 
reduced to 0.55 (0.23) in the SGLT2 inhibitor group.21 
Another relevant comparison is the PARADIGM-HF tri-
al (Prospective Comparison of ARNI with ACEI to De-
termine Impact on Global Mortality and Morbidity in 
Heart Failure). The annualized rate of decline in eGFR 
in the enalapril (control) group was 2.04 (2.21–1.88) 
mL·min–1·1.73 m–2, in comparison with 1.61 (1.77–
1.44) in the sacubitril/valsartan group; for comparison, 
the rate of decline in eGFR in DAPA-HF was reduced to 
1.09 (1.41–0.78) mL·min–1·1.73 m–2 per year. Because 
these 2 treatments are believed to work through dis-
tinct and likely complementary mechanisms, it is pos-
sible that they might have additive renal benefits in pa-
tients with HFrEF.
As expected, our patients with diabetes had a more 
rapid rate of decline in eGFR than patients without 
diabetes. We have reported that the benefits of dapa-
gliflozin on cardiovascular outcomes were consistent 
in patients with and without type 2 diabetes in DAPA-
HF.23 The current data extend these findings to the ef-
fect of SGLT2 inhibitors on kidney function, providing, 
we believe, the first evidence that SGLT2 inhibitors may 
have favorable renal effects in individuals without type 2 
diabetes. Other studies of the renal effects of SGLT2 in-
hibitors in individuals without type 2 diabetes have been 
small with relatively short follow-up and did not demon-
strate a significant effect on albuminuria.24 However, the 
protective effect of dapagliflozin in patents with CKD, 
but without diabetes, has been clearly demonstrated 
by the DAPA-CKD trial (Dapagliflozin and Prevention of 
Adverse Outcomes in Chronic Kidney Disease) and more 
data on the renal protective effects of SGLT2 inhibitors 
in individuals without type 2 diabetes will be provided 
by EMPA-KIDNEY (The Study of Heart and Kidney Pro-
tection With Empagliflozin; URL: https://www.clinicaltri-
als.gov; Unique identifier: NCT03594110).
The mechanism of the favorable effect of dapa-
gliflozin on eGFR in DAPA-HF is unknown. Although it 
may be the same as speculated in patients with type 2 
diabetes (reduction in intraglomerular pressure attribut-
able to enhanced tubulo-glomerular feedback),24,26–30 it 
is also possible that prevention of worsening of heart 
failure may play a role, as appears to be the case with sa-
cubitril/valsartan.31–32 It is likely that there is a detrimental 
bidirectional interplay between worsening heart failure 
and worsening renal function in HFrEF, and the preserva-
tion of kidney function in these patients is important.
Limitations
The most important limitation of the present analyses 
is the small number of renal end points that limited our 
ability to detect a benefit of dapagliflozin on renal out-
comes in this population. We are unable to determine 
the efficacy and safety of dapagliflozin at eGFR levels 
of <30 mL·min–1·1.73 m–2 because these patients were 
excluded from the trial. However, our data are consis-
tent with other trials that have enrolled patients with 
eGFR down to 30 mL·min–1·1.73 m–2. The longer-term 
trends in eGFR are limited by the relatively short fol-
low-up in trial (median follow-up was 18.2 months). 
However, our results are consistent with previous tri-
als. Only serious adverse events of interest were col-
lected, and, therefore, we do not have data on more 
common nonserious adverse events such as mycotic 
genital infections. Urinary albumin was not collected 
and therefore we were unable to assess the relationship 
with other markers of kidney function such as urinary 
albumin:creatinine ratio. Last, our data do not provide 
Table 5. Safety and Tolerability of Dapagliflozin by Baseline eGFR Group
Adverse events
eGFR <60 mL/min/1.73 m2
P value
eGFR ≥60 mL/min/1.73 m2
P value
Dapagliflozin Placebo Dapagliflozin Placebo
n=960 n=962 n=1407 n=1,405
Volume depletion, n (%) 97 (10.1) 86 (8.9) 0.39 81 (5.8) 76 (5.4) 0.74
Renal events, n (%) 97 (10.1) 115 (12.0) 0.22 56 (4.0) 55 (3.9) 1
Amputation, n (%) 8 (0.8) 9 (0.9) 1 5 (0.4) 3 (0.2) 0.73
Major hypoglycemia, n (%) 3 (0.3) 0 (0.0) 0.12 1 (0.1) 4 (0.3) 0.22
Fracture, n (%) 28 (2.9) 25 (2.6) 0.68 21 (1.5) 25 (1.8) 0.56
Permanent treatment 
discontinuation, n (%)
121 (12.6) 130 (13.5) 0.59 128 (9.1) 128 (9.1) 1
Any serious adverse event, 
n (%)
417 (43.4) 482 (50.1) 0.003 478 (34.0) 512 (36.4) 0.18
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any further information on how the SGLT2 inhibitors 
preserve kidney function, although they do confirm 
that the benefits extend to those without type 2 diabe-
tes and those with HFrEF.
Conclusion
In patients with HFrEF, morbidity, mortality, and symp-
toms were improved by dapagliflozin, in comparison 
with placebo, regardless of baseline kidney function. 
The favorable safety and tolerability profile of dapa-
gliflozin in comparison with placebo was not altered by 
baseline kidney function, and kidney function declined 
more slowly in patients who received dapagliflozin.
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